drugset
Drugs / Epstein-Barr Virus Specific Immunotherapy
last change Feb 2017 re-read 3 minutes ago

Epstein-Barr Virus Specific Immunotherapy

Cell therapy

Developed for
nasopharyngeal carcinoma
Investigated by
Brigham and Women's Hospital · Dana-Farber Cancer Institute · Massachusetts General Hospital · National Cancer Institute (NCI)

Trials 1

today NCT00834093 · Ph 2
2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00834093 Apr 2009 → Mar 2012 nasopharyngeal carcinoma Dana-Farber Cancer Institute Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Epstein-Barr Virus Specific Immunotherapy ClinicalTrials.gov intervention name — accepted as the source's own label NCT00834093 ↗
Modality Cell therapy “yielding an EBV-specific, autologous T cell product.” NCT00834093 ↗